Sign in
WithdrawnPhase 2

Ketamine for the Treatment for Alcohol Use Disorder in the ED

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
1 Sept 2023
Ended
19 Aug 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ketamine
  • Saline
Record updated
8 January 2025
Why it stopped
After months of screening, we screened 175 individuals, only 3 were eligible, 2 declined, and 1 was moved to a different floor before study activities were able to take place.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • English speaking adults aged 18 and above
  • Diagnosed with DSM5 alcohol use disorder, severe
  • Admitted to BWF inpatient withdrawal management unit (Addiction Recovery Program)

Who cannot take part

  • Alcohol withdrawal seizure prior to or during the ED visit
  • Current use of medications with known drug-drug interactions with ketamine (i.e., St. John's Wort, theophylline, opioid analgesics, CNS depressants other than benzodiazepines or phenobarbital)
  • Any psychotic disorder, bipolar disorder, active suicidality or homicidality
  • Systolic blood pressure persistently elevated above 180mmHg, or heart rate >130bmp, in the ED
  • History of hypersensitivity to ketamine, or experience of emergence reaction
  • History of any illicit or recreational use of ketamine
  • History of DSM5 hallucinogen use disorder, intracranial mass or bleed, porphyria, thyrotoxicosis, seizure disorder other than from alcohol withdrawal, liver cirrhosis, renal failure, obstructive lung disease, or sleep apnea
  • History within 6 months of head trauma, stroke, or myocardial infarction
  • Inability to perform consent due to impaired mental status
  • Clinical Institute Withdrawal Assessment (CIWA) score > 20 at any point in the ED
  • Receipt of ketamine treatment for depression in the past 3 months
  • Liver dysfunction with LFTs >3x upper normal limit
  • Pregnant

Where in United States

  • Brigham and Women's Faulkner HospitalBoston, United States

About the trial

What the trial wants to find out

The investigators' approach is to conduct a pilot double-blind, placebo-controlled randomized clinical trial with individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED) to receive either intravenous ketamine or saline placebo. The primary aim is to evaluate the intervention's safety. The secondary aim is to evaluate the preliminary efficacy of alcohol-related outcomes.

The 2 groups in the trial

  • KetamineTreatment being tested

    This arm will receive ketamine (n=25)

  • PlaceboPlacebo, for comparison

    This arm will receive the saline placebo (n=25)

    Treatment: Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ketamine for the Treatment for Alcohol Use Disorder in the Emergency Department: A Pilot Double-blind, Placebo-controlled Randomized Clinical Trial
Record updated
8 January 2025